QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VolitionRx Ltd. (VNRX) CEO Cameron Reynolds Joins SNN Live To Discuss Revolutionary Colorectal Cancer Test 0 comments
    Dec 16, 2013 5:37 PM | about stocks: VNRX

    More than 5,600 miles from the company's home-base in Namur, Belgium, VolitionRx CEO Cameron Reynolds recently interviewed with SNN Live host and CEO Shelly Kraft at the Sixth Annual LD Micro Conference in Bel Air, Calif.

    VolitionRx is a life sciences company developing inexpensive, accurate, and scalable cancer detection blood tests. In the live video interview, Reynolds discusses the ongoing clinical trial for the company's front-line colorectal cancer diagnostic test.

    To view the interview visit: www.youtube.com/watch?v=mh08N2_LPLg

    Reynolds notes that while colonoscopies are the standard procedure for colorectal cancer diagnosis, 50 percent of individuals do not undergo the procedure. Though highly accurate, the testing is highly invasive and costs roughly $2,000.

    VolitionRx's blood diagnostic test, however, is cheaper, quicker and in pre-clinical trials demonstrated significant accuracy. The company hopes that the blood-based tests will encourage more people to get routine testing.

    "Blood tests, we think, are very superior for ease and for price," says Reynolds. " … Accuracy is very important to us, and that's why we've developed a test that appears to be very accurate in our early stage trials …. The accuracy of our tests …are about 85 percent for both false-negatives and false-positives. For blood tests [this result] is excellent. It's something we're very hopeful for, to continue on those sort of numbers in the larger trials we're doing now."

    The company's test isn't designed to replace colonoscopy, which can identify the location of cancerous regions in the bowel, but rather to replace the colonoscopy as an accurate, low-cost and minimally invasive front-line screening test.

    Reynolds concludes his interview with SNN Live by briefly discussing his own background, as well as that of the company's scientific team.

    For more information on VolitionRx, visit volitionrx.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: VNRX
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.